

**NORE (Network of Orthopaedic Registries of Europe) an EFORT
standing committee
NIMAC symposium**

**Engaging with the new EU regulatory landscape
for medical devices.**

Challenges and opportunities

Luca Orlandini MD

Vice President Global Medical Affairs

Smith&Nephew Orthopaedics AG

Switzerland


Brussels April 6 2018

Session 3: What to do next, quality and safety for future patients

The future from the eyes of a surgeon who is also connected to a manufacturer

When therapeutic choices include implantable devices what primarily count is:

- Safety of the implant
- Performance to be evaluated both as therapeutic efficacy and efficiency
- Degree of patient satisfaction



MDR aims to...

- Significant **changes to product introduction**
- **Risk reduction and monitoring** via premarket scrutiny and post market surveillance
- **Increased evidence** (premarket, clinical and technical) for approvals
- To improve **quality and safety** of medical devices for patients
- It is closely aligned with **device effectiveness/performance**
- To increase in market **safety and monitoring**
- Monitoring and **compliance** through product lifetime
- Make public health **information accessible**

MDR Context

MDD

- 20 articles
- 60 pages
- 12 annexes

Directives: Legislation that sets out general rules that are then transferred into national law by each member state.

Under the **MDD**:
manufacturer could certify met technical requirements and place on the market

MDR

- 97 articles
- 369 pages
- 16 annexes

Regulations: Legislation that is directly applicable in all EU member states; no room for local interpretation.

Under the **MDR**: manufacturers **MUST** provide evidence on clinical benefit to patients

Rules to be fulfilled in order to CE mark a medical device and make it available on the CE-recognizing markets

Stands alone, not following FDA or other bodies



Risk Benefit Assessment to the patient

Manufacturers must:


Prove reduced patient risk **as much as possible** pre-market

Continuously assess the risks and anticipated benefits post launch throughout product lifecycle

Provide overall evaluation of **acceptability of the benefit/risk profile**
(incl different patient populations)



The MDR has Implications Across the Whole Product Lifecycle



Actual main sources for Performance demonstration

Clinical investigations (including RCTs) and PMCFUs

Registries (when available)

Actual main sources for Safety demonstration

Clinical Investigations (including RCTs) and PMCFUs

Registries (when available)

All PMS data including complaints

ADEs and SADEs detection some Registries are probably tailored from a numeric point of view to provide meaningful informations for relatively common AEs (1 to 0.5% occurrence rate)

Expected incidence of adverse events	1 event	2 events	3 events
1 in 100	300	480	650
1 in 200	600	960	1300
1 in 1100	3000	4800	6500
1 in 2000	6000	9600	13000
1 in 10000	30000	48000	65000



Source: *Safety requirements for the first use of new drugs and diagnostic agents in man.* Geneva CIOMS(WHO) 1983

What about patient satisfaction?



Registries will not limit to record revisions only but start to introduce regular scheduled FUs to capture clinical outcome and PROMs?

patients/yr	3500															
	yr 0	yr 1	yr 2	yr 3	yr 4	yr 5	yr 6	yr 7	yr 8	yr 9	yr 10	yr 11	yr 12	yr 13	yr 14	yr 15
censoring						0.02		0.03			0.05					0.1
f.u. in loco	xxx	x			(x)	x	(x)			(x)	x	(x)			(x)	x
f.u. teleffon		(x)	x	(x)			(x)	x	(x)							

	IN LOCO	TELEFON
controls/hour	5	5
hours/day	3	8
days/week	5	5
weeks/year	50	50




■ Controls
■ Tolerance (worst case)



- A Patient-Reported Outcome Measurement (PROM) is a health outcome directly reported by the patient who experiences it.
- PROMs measure a patient's health status or health related quality of life at a single point in time.
- Traditional PROMs may be over 40 questions long. A reliable system, customized to the patient that uses less questions has been developed, validated and is available

innovation in PROMs for TKA patients


PROMs collected using an electronic tool (smartphone) and sent to the surgeon's computer...



App



Built using PROMIS knowledge



Administered using Computer Adaptive Tests (CATs)

- Physical Function CAT
- Pain Behaviour CAT
- Pain Interference CAT
- Depression CAT

What is the Patient-Reported Outcomes Measurement Information System[®]? (PROMIS)

- Developed and evaluated using state-of-the science psychometric methods funded by the NIH.
- Measures used to evaluate and monitor physical, mental, and social health.
- Relevant across all conditions – they are not disease specific.
- Scores on one metric – gives a score between 20 and 80.

COMPUTER ADAPTIVE TESTS (CATs) on the app

- Individually tailored electronic questionnaires
- Focused on a single domain
- Next item administered from item bank depends on previous answers
- Typically 5-7 questions.

Think of it as intelligent questioning...




If this person says they cannot walk 1 mile without pain, there is no need to ask any questions related to sport etc.

The focus is on calibrating just how bad their pain interference is...

Compare this to traditional PROMs where every question must be asked...

Moticon's OpenGo






3 component categories

-  SENSOR INSOLES
-  SOFTWARE
-  ACCESSORIES

Operation overview


1 2 3

-  LIVE Data streamed in real time
-  RECORDING Data stored for later bluetooth transmission
-  SLEEP Energy conservation when not in use

What does the sensor insole measure?



- Each insole contains 14 sensors
 - 13 capacitive pressure sensors
 - 3 accelerometer



Sensor overview

Each sensor insole contains 13 capacitive pressure sensing pads and a 3D accelerometer for measuring motion.

The sensor data is processed in the embedded microsystem. From this raw data, a variety of essential gait and motion parameters are computed.

What does the sensor insole measure?



<http://moticon.de/products/science-research>

Conclusions: how may the future look like?

- No «fit for all» single solution
- No need to duplicate data with a different methodological approach if data already exist
- Patients' own appreciation unavoidable
- Take into account overall sustainability (financial and human resources) of the projects
- Exploit new technological approaches to generate evidence
- Evidence will possibly be generated by a well balanced mix of different approaches each conceived and properly weighted in the Critical Appraisal Process